| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
An economic analysis of human papillomavirus triage for the management of women with atypical and abnormal Pap smear results in Germany
|
Sheriff, Sara K.
|
|
2007
|
8 |
2 |
p. 153-160
|
artikel
|
| 2 |
Comment on: Should we really worry about “launch delays” of new drugs in OECD countries? by L. Garatinni and S. Ghislandi
|
Cohen, Joshua
|
|
2007
|
8 |
2 |
p. 169-170
|
artikel
|
| 3 |
Comparative cost-minimisation of oral and intravenous chemotherapy for first-line treatment of non-small cell lung cancer in the UK NHS system
|
Le Lay, K.
|
|
2007
|
8 |
2 |
p. 145-151
|
artikel
|
| 4 |
Discussion point: should governments buy drug patents?
|
Llano, Juan del
|
|
2007
|
8 |
2 |
p. 173-177
|
artikel
|
| 5 |
Health economic implications of irbesartan treatment versus standard blood pressure control in patients with type 2 diabetes, hypertension and renal disease: a Hungarian analysis
|
Palmer, Andrew J.
|
|
2007
|
8 |
2 |
p. 161-168
|
artikel
|
| 6 |
Modelling the 5-year cost effectiveness of tiotropium, salmeterol and ipratropium for the treatment of chronic obstructive pulmonary disease in Spain
|
Rutten-van Mölken, Maureen P. M. H.
|
|
2007
|
8 |
2 |
p. 123-135
|
artikel
|
| 7 |
Patient access to rheumatoid arthritis treatments
|
Jönsson, Bengt
|
|
2007
|
8 |
2 |
p. 33-34
|
artikel
|
| 8 |
Patient access to rheumatoid arthritis treatments
|
Jönsson, Bengt
|
|
2007
|
8 |
2 |
p. 35-38
|
artikel
|
| 9 |
Patients’ willingness to pay for electronic communication with their general practitioner
|
Bergmo, Trine Strand
|
|
2006
|
8 |
2 |
p. 105-110
|
artikel
|
| 10 |
Pharmacoeconomic studies in Italy: a critical review of the literature
|
Cornago, D.
|
|
2006
|
8 |
2 |
p. 89-95
|
artikel
|
| 11 |
Should we really worry about “launch delays” of new drugs in OECD countries? Reply to J Cohen
|
Garattini, Livio
|
|
2007
|
8 |
2 |
p. 171
|
artikel
|
| 12 |
Systematic review of economic evaluations and cost analyses of guideline implementation strategies
|
Vale, Luke
|
|
2007
|
8 |
2 |
p. 111-121
|
artikel
|
| 13 |
The burden of rheumatoid arthritis and access to treatment: a medical overview
|
Smolen, J.
|
|
2007
|
8 |
2 |
p. 39-47
|
artikel
|
| 14 |
The burden of rheumatoid arthritis and access to treatment: determinants of access
|
Lundqvist, J.
|
|
2007
|
8 |
2 |
p. 87-93
|
artikel
|
| 15 |
The burden of rheumatoid arthritis and access to treatment: health burden and costs
|
Lundkvist, J.
|
|
2007
|
8 |
2 |
p. 49-60
|
artikel
|
| 16 |
The burden of rheumatoid arthritis and access to treatment: outcome and cost-utility of treatments
|
Kobelt, G.
|
|
2007
|
8 |
2 |
p. 95-106
|
artikel
|
| 17 |
The burden of rheumatoid arthritis and access to treatment: uptake of new therapies
|
Jönsson, B.
|
|
2007
|
8 |
2 |
p. 61-86
|
artikel
|
| 18 |
The burden of type 2 diabetes in Serbia and the cost-effectiveness of its management
|
Bjegovic, Vesna
|
|
2006
|
8 |
2 |
p. 97-103
|
artikel
|
| 19 |
The cost-utility of magnetic resonance imaging for breast cancer in BRCA1 mutation carriers aged 30–49
|
Norman, Richard P. A.
|
|
2007
|
8 |
2 |
p. 137-144
|
artikel
|
| 20 |
The time for cost-effectiveness in the new European Union member states: the development and role of health economics and technology assessment in the mirror of the Hungarian experience
|
Gulácsi, László
|
|
2007
|
8 |
2 |
p. 83-88
|
artikel
|
Tijdschrift beschrijving